{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:34:55Z","timestamp":1721342095659},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1097\/md.0000000000007901","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:13:33Z","timestamp":1503447213000},"page":"e7901","source":"Crossref","is-referenced-by-count":6,"title":["The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome"],"prefix":"10.1097","volume":"96","author":[{"given":"Sung Soo","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Min","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mijin","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Jungsik","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-48-20210226","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","article-title":"Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis","volume":"139","author":"Rosado","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"R2-48-20210226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","article-title":"Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes","volume":"59","author":"Canna","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"R3-48-20210226","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R4-48-20210226","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fped.2016.00047","article-title":"Hemophagocytic lymphohistiocytosis in children: pathogenesis and treatment","volume":"4","author":"Ishii","year":"2016","journal-title":"Front Pediatr"},{"key":"R5-48-20210226","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/BOR.0000000000000093","article-title":"Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis","volume":"26","author":"Weaver","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R6-48-20210226","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0885066613517076","article-title":"Hemophagocytic syndrome and critical illness: new insights into diagnosis and management","volume":"30","author":"Tothova","year":"2015","journal-title":"J Intensive Care Med"},{"key":"R7-48-20210226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.hoc.2015.06.009","article-title":"Hemophagocytic lymphohistiocytosis in adults","volume":"29","author":"Campo","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"R8-48-20210226","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"R9-48-20210226","doi-asserted-by":"crossref","first-page":"623036","DOI":"10.1155\/2013\/623036","article-title":"The use of (18)F-FDG-PET\/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases","volume":"2013","author":"Glaudemans","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"R10-48-20210226","first-page":"35","article-title":"18F-FDG PET and PET\/CT in fever of unknown origin, Journal of nuclear medicine: official publication","volume":"48","author":"Meller","year":"2007","journal-title":"Soc Nucl Med"},{"key":"R11-48-20210226","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.116.180729","article-title":"Evaluation of spleen glucose metabolism using 18F-FDG PET\/CT in patients with febrile autoimmune disease","volume":"58","author":"Ahn","year":"2017","journal-title":"J Nucl Med"},{"key":"R12-48-20210226","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R13-48-20210226","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R14-48-20210226","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R15-48-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1074\/jbc.R115.693903","article-title":"Immunometabolism: cellular metabolism turns immune regulator","volume":"291","author":"Loftus","year":"2016","journal-title":"J Biol Chem"},{"key":"R16-48-20210226","doi-asserted-by":"crossref","first-page":"805975","DOI":"10.1155\/2013\/805975","article-title":"Targeting metabolism to induce cell death in cancer cells and cancer stem cells","volume":"2013","author":"Pecqueur","year":"2013","journal-title":"Int J Cell Biol"},{"key":"R17-48-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3348\/kjr.2013.14.1.1","article-title":"Prognostic significance of volume-based PET parameters in cancer patients","volume":"14","author":"Moon","year":"2013","journal-title":"Korean J Radiol"},{"key":"R18-48-20210226","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s13075-014-0423-2","article-title":"Clinical value of whole-body PET\/CT in patients with active rheumatic diseases","volume":"16","author":"Yamashita","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R19-48-20210226","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/1744666X.2015.1058159","article-title":"Clinical features and correct diagnosis of macrophage activation syndrome","volume":"11","author":"Cron","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"R20-48-20210226","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2016.09.016","article-title":"Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers","volume":"16","author":"Ruscitti","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R21-48-20210226","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Ann Rev Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:30:41Z","timestamp":1620959441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201708250-00048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":21,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007901","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}